The study conducted by Dr. Erminia Massarelli focused on evaluating the combination of osimertinib and consolidative stereotactic ablative radiation (SABR) for the treatment of advanced EGFR-mutant non-small cell lung cancer (NSCLC). This study was carried out in collaboration with UT Southwestern and included 43 untreated patients with metastatic and incurable disease.
The results of the study indicated that patients who received osimertinib and SABR showed significant improvements in both progression-free survival and overall survival compared to the historical control group. The progression-free survival was extended to about 32 months, while the overall survival reached 42 months. These findings suggest that the combination therapy could provide long-term benefits for patients with EGFR-mutant NSCLC.
Despite the limitations of the study, including its small sample size, the low incidence of significant toxicities is promising. Only 2% of patients experienced pneumonitis, with other toxicities such as hyponatremia, skin toxicity, and diarrhea also reported. This suggests that the combination of osimertinib and SABR could be a viable treatment option in the future.
The study conducted by Dr. Erminia Massarelli sheds light on the potential benefits of combining osimertinib with consolidative SABR for the treatment of advanced EGFR-mutant NSCLC. The positive outcomes in terms of progression-free survival and overall survival highlight the importance of further research in this area to provide improved treatment options for patients with this type of lung cancer.
Leave a Reply